Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Definitive Healthcare (DH) EBITDA (2020 - 2026)

Definitive Healthcare filings provide 6 years of EBITDA readings, the most recent being -$26.6 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 73.26% to -$26.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$224.3 million, a 68.45% increase, with the full-year FY2025 number at -$224.3 million, up 68.45% from a year prior.
  • EBITDA hit -$26.6 million in Q4 2025 for Definitive Healthcare, down from -$8.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.6 million in Q1 2021 to a low of -$369.6 million in Q2 2024.
  • Median EBITDA over the past 5 years was -$12.0 million (2022), compared with a mean of -$66.8 million.
  • Biggest five-year swings in EBITDA: plummeted 2962.22% in 2024 and later surged 98.87% in 2025.
  • Definitive Healthcare's EBITDA stood at -$13.1 million in 2021, then grew by 19.55% to -$10.5 million in 2022, then increased by 4.34% to -$10.1 million in 2023, then plummeted by 887.73% to -$99.6 million in 2024, then surged by 73.26% to -$26.6 million in 2025.
  • The last three reported values for EBITDA were -$26.6 million (Q4 2025), -$8.7 million (Q3 2025), and -$4.2 million (Q2 2025) per Business Quant data.